EGFR Mutations in NSCLC

Tumor Types & Biomarkers
Tumor Types & Biomarkers

Explore clinical guidelines on why, whom and how to test actionable biomarkers in lung, breast, ovarian and prostate cancers.
- Lung Tumor
  
  EGFR
  
  ERBB2 (HER2)
- Breast Tumor
  
  BRCA1/2
  
  ESR1
  
  HER2
  
  PIK3CA/AKT1/PTEN
- Ovarian Tumor
  
  HRD
- Prostate Tumor
  
  HRRm
  
  PTEN
Testing Solutions
Explore Precision Medicine

Explore Precision Medicine

Implement best practices in your workflow and discover how recent advances are optimizing precision medicine.

Realizing the Potential of Precision Medicine

Collaborate across the MDT to address health inequities and optimize testing pathways.
Realizing the Potential of Precision Medicine

Latest Developments in Precision Medicine

Explore recent advances in diagnostic technologies and novel biomarkers to support precision medicine in your practice.
Latest Developments in Precision Medicine
Resources

Resources

Access a range of resources you can apply in your practice.

FAQs

Find answers to frequently asked questions about precision medicine.
FAQs

Find a Testing Lab

Search our directory of major laboratories that perform diagnostic biomarker testing.
Find a Testing Lab

Glossary

Find definitions for the most commonly used terms in precision medicine.
Glossary

Resource Library

Explore our library of videos and downloadable tools to help optimize your practice and inform your patients.
Resource Library

My Favorites

Personalize your learning by creating a bespoke collection of precision medicine resources.
My Favorites
Our Team

Subscribe Connect with us

EGFR

EGFR

Jump to:

Testing Recommendations
Prevalence
Sample Type
Diagnostic Assays
Interpreting & Reporting
Considerations for Your Practice
Helpful Resources

Testing for EGFR Mutations in Lung Cancer Can Help Guide Treatment Decisions^2,3

Epidermal growth factor receptor (EGFR) mutations are actionable in non-small cell lung cancer (NSCLC), making them a potential target for therapy. ²

EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer.

NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) Recommend Testing for EGFR Mutations in NSCLC Stage IB—IIIA, IIIB (T3, N2) and Stage IV NSCLC³

^aThe NCCN Guidelines for NSCLC provide recommendations for individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays or commercial laboratories.³ ^bNCCN also recommends testing for ALK rearrangements, BRAF mutations, ROS1 gene rearrangements, RET gene rearrangements, MET exon 14–skipping mutations, NTRK1/2/3 gene fusions, KRAS mutations, ERBB2 (HER2) mutations, and PD-L1 status in eligible people with advanced or mNSCLC.³

ALK, anaplastic lymphoma kinase; BRAF, v-Raf murine sarcoma viral oncogene homolog B; EGFR, epidermal growth factor receptor; ERBB2, erb-b2 receptor tyrosine kinase 2; FDA, US Food and Drug Administration; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; N2, node 2; NCCN, National Comprehensive Cancer Network; NGS, next-generation sequencing; NTRK, neurotrophic tyrosine receptor kinase; NSCLC, non-small cell lung cancer; mNSCLC, metastatic non-small cell lung cancer; MET, mesenchymal-epithelial transition; PD-L1, programmed death-ligand 1; RET, rearranged during transfection; ROS1, ROS proto-oncogene 1, receptor tyrosine kinase; T3, tumor 3.

EGFR Mutations Are One of the Most Common Actionable Oncogenic Drivers in NSCLC⁸

Diagram representing prevalence of EGFR mutations in NSCLC

Up to

~1 in 5

patients with stage I–III NSCLC may have an EGFR mutation^9,10,a

Up to

57%

of patients with stage IB–III EGFRm NSCLC also express PD–L1 at levels ≥1%^11,b

PD-L1

EGFRm
&
PD-L1

EGFRm

^aPrevalence of EGFR mutations in NSCLC adenocarcinoma was based on data from 2 references: Sholl et al (2015) performed mutation analysis on 1007 cases with confirmed diagnosis of lung adenocarcinoma. Testing was performed on 987 cases for EGFR sensitizing mutations (exon 19 deletions, EGFR L858R mutations, EGFR G719S mutations, EGFR L861Q mutations) and other EGFR mutations (any one or more mutations in EGFR other than those mentioned previously). Out of 987 cases, 331 cases that were analyzed had stage I-III NSCLC. D’Angelo et al (2012) analyzed tumor specimens from a cohort of 1118 people with stage I-III surgically resected lung adenocarcinomas with EGFR exon 19 deletions and L858R mutations only.^{9,10 b}EGFR mutation status and PD-L1 expression overlap was examined in a retrospective analysis of 319 people with EGFRm NSCLC across all stages. EGFR mutations included exon 19 deletions (n=145), exon 21 L858R mutations (n=121), exon 19 nondeletions (n=26), exon 21 non-L858R mutations (n=3), exon 18 mutations (n=12), and exon 20 mutations (n=8). One person had both exon 18 and exon 20 mutations and 3 people had other mutations. PD-L1 expression ≥1% was observed in 86 out of 150 people with stage IB-III EGFRm NSCLC.¹¹

EGFR, epidermal growth factor receptor; EGFRm, epidermal growth factor receptor mutation-positive; NSCLC, non-small cell lung cancer; PD-L1, programmed death-ligand 1.

Diagram representing prevalence of EGFR mutations in NSCLC 2

Up to

~1 in 4

patients with mNSCLC may have an EGFR mutation^8,a

Up to

~60%

of patients with EGFRm NSCLC also express PD-L1 at levels ≥1%^12–15,b

PD-L1

EGFRm
&
PD-L1

EGFRm

NCCN Guidelines state that:

In mNSCLC, knowing PD-L1 status is not enough to make 1L treatment decisions as targeted therapy for the oncogenic driver should take precedence.³

Increased EGFR signaling promotes tumor cell growth and survival^2,16

EGFR mutations may lead to unregulated proliferation and survival of tumor cells, making them a key molecular driver of disease, regardless of disease stage.^2,16

^aJordan et al (2017) prospectively analyzed a total of 915 tumors from 860 patients with recurrent or metastatic lung adenocarcinoma for mutations in >300 cancer-associated genes using the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) assay, a hybridization capture-based, next-generation sequencing platform.^8 bMazieres et al (2019) was a multicenter, international, retrospective study of 551 patients receiving ICI monotherapy for advanced NSCLC with at least one oncogenic driver alteration. 125 patients had an EGFR mutation. D'Incecco et al (2015) was a multicenter, retrospective, Italian study that assessed PD-L1 expression in 125 patients with mNSCLC and EGFR mutations, ALK translocations, or KRAS mutations. 56 patients had an EGFR mutation. Dietel et al (2019) was a multicenter, international, retrospective study that examined PD-L1 expression in 2368 tumor samples with histologically confirmed stage IIIB/IV primary NSCLC as classified by AJCC 7th edition. 448 patients had an EGFR mutation. Brown et al (2019) analyzed PD-L1 expression in 231 samples of untreated EGFR-mutated advanced NSCLC from the FLAURA trial of osimertinib.^12–15

1L, first-line; ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; EGFRm, epidermal growth factor receptor mutation-positive; ICI, immune checkpoint inhibitor; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; mNSCLC, metastatic non-small cell lung cancer; NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand-1.

Consider Sample Type by Specimen and Assay Availability to Maximize Detection of Therapeutically Actionable Mutations

ctDNA testing
Tissue testing

Integrating ctDNA alongside tissue testing may help reduce turnaround time and maximize identification of driver gene mutations in mNSCLC.^3,17

Sample type	Clinical relevance	Limitations
Tissue specimen (diagnostic biopsy)	Tissue specimens (including resections) provide high tumor volume, which may help ensure adequate tissue for molecular testing¹⁸ Well-established and commonly used at diagnosis when tissue is collected as part of routine workup^17,19	QNS and/or prolonged turnaround time can delay treatment planning²⁰
Cytology specimen (diagnostic)	Biomarker testing of cytology specimens from pleural fluid can be used as an alternative to tissue testing²¹	Cytology specimens may provide limited material which may pose challenges for pathology²²
Liquid biopsy (ctDNA)	Minimally invasive, requires only a small amount of blood, and avoids complications of biopsies²³ Likely to better reflect tumor heterogeneity²³	Lower tumor burden may decrease sensitivity of ctDNA analysis²⁴
Concurrent liquid biopsy (ctDNA) and tissue biopsy	Concurrent testing may: Deliver comprehensive results faster³ Help provide actionable results even in cases of tissue QNS^25,a Maximize the detection of therapeutically actionable mutations^25,26,a,b Reduce time to diagnosis which may result in earlier initiation of appropriate treatment^27,c Negative results by one method suggests the use of a complementary method³	Lack of standardization and training prevents implementation into clinical routine²⁸

Unlike ctDNA analysis used in mNSCLC, liquid biopsy (ctDNA) molecular testing has not been clinically validated in the resectable NSCLC setting.^29,34

Mutation detection in ctDNA may be challenging in the resectable setting due to lower tumor burden and less shedding of tumor DNA.^29,34

Tissue testing remains essential in resectable and metastatic settings, while plasma ctDNA is only clinically validated in mNSCLC.^19,29

Sample type	Clinical relevance	Limitations
Tissue specimen (preoperative biopsy)	A preoperative biopsy may be useful for patients with ≥Stage IB NSCLC who may be candidates for systemic therapy prior to surgery³	Preoperative biopsy samples may not always be sufficient for both diagnosis and biomarker testing³⁰
Tissue specimen (surgical resection sample)	Surgically resected tissue provides high tumor volume, which may help ensure adequate tissue for molecular testing³⁰	Can be painful, invasive, costly, and time consuming³¹
Cytology specimen	Cytology specimens with adequate cellularity and preservation are suitable for biomarker testing according to the CAP/IASLC/AMP guidelines³² The diagnosis of NSCLC made on cytology (sputum, TTNA, bronchoscopic specimens, or pleural fluid) is reliable in people suspected of having NSCLC³³ However, adequate tissue should be obtained to accurately define the histological type and to perform molecular analysis when applicable³³	Cytology specimens may provide limited material which may pose challenges for pathology²²

Mutation detection in ctDNA may be challenging in the resectable setting due to lower tumor burden and less shedding of tumor DNA.^29,34

^aIn a single center prospective, cohort study of 323 patients with mNSCLC, 229 received concurrent testing. Therapeutically targetable mutations were detected in 113 patients, among whom 66 had the mutation detected in plasma only, 16 patients in tissue only, and 31 patients in plasma and tissue. Mutations for 35 of 113 patients (31%) were detected in plasma only when tissue DNA was insufficient or unavailable, or no mutation was detected in tissue.^25 bIn a prospective analysis of 282 patients with previously untreated mNSCLC undergoing physician discretion SOC tissue genotyping and submitted a pre-treatment blood sample for comprehensive cfDNA analysis, the addition of cfDNA testing identified a guideline recommended biomarker in 32% (n=90/282) of patients who otherwise would not have had guideline-complete genotyping.^26 cA retrospective study comparing patients with mNSCLC who underwent tissue genotyping alone (n=78) vs patients who underwent concurrent liquid and tissue genotyping (n=42) revealed a shorter mean time to diagnosis when undergoing concurrent testing (33.5 days vs 20.6 days respectively; p<0.001).²⁷

AMP, Association for Molecular Pathology; CAP, College of American Pathologists; cfDNA, cell-free deoxyribonucleic acid; ctDNA, circulating tumor deoxyribonucleic acid; EGFR, epidermal growth factor receptor; IASLC, International Association for the Study of Lung Cancer; mNSCLC, metastatic non-small cell lung cancer; NCCN, National Comprehensive Cancer Network^®(NCCN^®); NSCLC, non-small cell lung cancer; QNS, quantity not sufficient; SoC, standard of care; TTNA, transthoracic needle aspiration.

Utilize Diagnostic Assays for EGFR Mutation Testing to Help Inform Treatment Options³⁵

Results may be ready in hours to within 2 weeks, depending on the type of test and where it is done^a

Laboratory and test name	Genes or alterations assessed	Minimum sample requirements	Turnaround time
Send-out
Foundation Medicine FoundationOne^®CDx^5,6,36,b	324	FFPE block or ≥11 unstained slides	Median 8.8 days
Foundation Medicine FoundationOne^®LiquidCDx^37,b	>300	Blood: 2 tubes, 8.5 mL each	<2 weeks
Guardant Health Guardant360^® CDx^38,39,b	55	Blood: Minimum of 5 mL	≤7 days
Caris^® Life Sciences Caris Molecular Intelligence^® Tumor Profiling^40,41,b	~23,000	FFPE block or 25 unstained slides	10–14 days
TEMPUS Tempus xT (RUO)^42,43,c	648	FFPE block or 10 unstained slides + 1 H&E slide	9 days
NeoGenomics NeoTYPE^® Lung Tumor Profile (RUO)^44,c	Analyzes 49 biomarkers through a combination of methods	FFPE tissue (block)	14 days
In house
Thermo Fisher Oncomine^TM Dx Target Test^45,b	23	10 ng of DNA and RNA from FFPE tissue	4 days
Roche cobas^® EGFR Mutation Test v2 Solid Tumor^4,46,47,b	1	1 × 5 μm FFPE tissue section OR 2 mL plasma	<8 hours for tissue workflow and <4 hours for plasma workflow
Qiagen therascreen^® EGFR RGQ PCR^48,b	1	FFPE clock	Not reported
Biocartis Idylla^TM EGFR Mutation Assay (RUO)^49,c	1	1 × 5 μm FFPE tissue section	2.5 hours
Thermo Fisher Oncomine™ Precision Assay (RUO)^50,c	50	10 ng of DNA or RNA	1 day

Represents laboratories or assays that offer concurrent testing

AstraZeneca is not affiliated with and does not control these websites. Inclusion of a website on AZPrecisionMed.com does not constitute endorsement of its content by the associated organizations.

^aThis document is intended as educational information and is not intended as a complete list of available testing options. AstraZeneca is not responsible for any test provider and does not endorse any particular diagnostic test. The accuracy and results of diagnostic tests vary, and AstraZeneca shall have no liability arising from such testing. Information provided herein should in no way be considered a guarantee of coverage, reimbursement, or patient assistance. Providers should contact third-party laboratories for information on their patient assistance programs. While diagnostic testing may assist providers in identifying appropriate treatment for patients, the decision and action should be decided by a provider in consultation with the patient. All products are trademarks of their respective holders, all rights reserved. ^bFDA approved companion diagnostic.^cThis assay is not an FDA-approved companion diagnostic. The listed mutations detected by this assay could be informative for the treatment of NSCLC.

CDx, companion diagnostic; cfDNA, circulating cell-free deoxyribonucleic acid; DNA, deoxyribonucleic acid; EGFR, epidermal growth factor receptor; FDA, US Food and Drug Administration; FFPE, formalin-fixed paraffin-embedded; H&E, hematoxylin and eosin; NSCLC, non-small cell lung cancer; PCR, polymerase chain reaction; RNA, ribonucleic acid; RUO, research use only.

Scientist looking at and holding lab samples

Browse a selection of major laboratories offering a range of biomarker testing options.

Find a testing lab

This information is intended as educational and is not intended as a complete list of available testing options. AstraZeneca is not responsible for any test provider and does not endorse any particular diagnostic test. The accuracy and results of diagnostic tests vary, and AstraZeneca shall have no liability arising from such testing. Information provided herein should in no way be considered a guarantee of coverage, reimbursement, or patient assistance. Providers should contact third-party laboratories for information on their patient assistance programs. While diagnostic testing may assist providers in identifying appropriate treatment for patients, the decision and action should be decided by a provider in consultation with the patient. All products are trademarks of their respective holders, all rights reserved.

Find a list of FDA cleared or approved companion diagnostics.³⁵

View diagnostic devices

AstraZeneca is not affiliated with and does not control these websites. Inclusion of a website on AZPrecisionMed.com does not constitute endorsement of its content by the associated organizations.

FDA, US Food and Drug Administration.

Accurate Interpretation and Reporting of Biomarker Test Results May Help to Ensure an Appropriate Diagnosis⁵¹

The American Society of Clinical Oncology has provided guidance on information to include for biomarker test reporting in cancer.

Reports should include basic information about the test such as⁵¹:

Detection limits

Genes and gene regions evaluated

Variants detected

Including single nucleotide variants, insertion/deletion mutations, copy number variations, gene fusions, and gene expression

Variants that may not be detected

The College of American Pathologists provides a template for interpreting and reporting results of biomarker testing of specimens from patients with NSCLC.⁵²

View CAP reporting template

Two healthcare providers looking at a computer screen

CAP, College of American Pathologists; NSCLC, non-small cell lung cancer.

Considerations for Your Practice

Implement EGFR mutation testing protocols or standardize those already in place to ensure all eligible people with NSCLC can receive fully informed treatment options.

Follow NCCN Guidelines recommending EGFR testing for eligible patients with resectable stage IB to IIIA and stage IIIB (T3, N2) NSCLC
Find solutions to common challenges you may face during biomarker testing

EGFR, epidermal growth factor receptor; NCCN, National Comprehensive Cancer Network; NSCLC, non-small cell lung cancer.

Helpful Resources

Check out these featured resources on EGFR biomarker testing in lung cancer.

EGFR, epidermal growth factor receptor; EGFRm, epidermal growth factor receptor mutation-positive; mNSCLC, metastatic non-small cell lung cancer; NSCLC, non-small cell lung cancer.

Le X, et al. Cancers (Basel). 2023;15(11):2917.
Chevallier M, et al. World J Clin Oncol. 2021;12(4):217–237.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Non-Small Cell Lung Cancer. V.11.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed October 22, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org.
Roche Diagnostics. cobas^® DNA Sample Preparation Kit. Accessed September 03, 2024. https://diagnostics.roche.com/us/en/products/params/cobas-dna-sample-preparationkit.html
Foundation Medicine. FoundationOne^® CDx Specimen Instructions. Accessed September 03, 2024. https://info.foundationmedicine.com/hubfs/FMI Labels/FoundationOne_CDx_Label_Technical_Info.pdf
Foundation Medicine. What is FoundationOne^® CDx? Accessed September 03, 2024. https://www.foundationmedicine.com/test/foundationone-cdx
NeoGenomics. PD-L1 22C3 FDA for NSCLC. Accessed September 03, 2024. https://neogenomics.com/test-menu/pd-l1-22c3-fda-nsclc
Jordan EJ, et al. Cancer Discov. 2017;7(6):596–609.
Sholl LM, et al. J Thorac Oncol. 2015;10(5):768–777 + suppl appendix 1&2.
D’Angelo SP, et al. J Thorac Oncol. 2012;7(12):1815–1822[ST2].
Cho JH, et al. Cancer Res Treat. 2018;50(1):95–102.
Mazieres J, et al. Article and supplementary material. Ann Oncol. 2019;30(8):1321–1328.
D’Incecco A, et al. Br J Cancer. 2015;112(1):95–102.
Brown H, et al. J Thorac Oncol. 2020;15(1):138–143.
Dietel M, et al. Lung Cancer. 2019;134:174–179.
Black RC and Khurshid H. R I Med J. 2015;98(10):25–28.
Rolfo C, et al. J Thorac Oncol. 2018;13(9):1248–1268.
Lim C, et al. Curr Oncol. 2017;24(2):103–110.
Ofiara LM, et al. Front Oncol. 2014;4:253.
Gregg JP, et al. Transl Lung Cancer Res. 2019;8(3):286–301.
Ellison G, et al. J Clin Pathol. 2013;66:79–89.
Bubendorf L, et al. Eur Respir Rev. 2017;26(144):170007.
Ilié M and Hofman P. Transl Lung Cancer Res. 2016;5(4):420–423.
Semenkovich NP, et al. J Immunother Cancer. 2023;11:e006284.
Aggarwal C, et al. JAMA Oncol. 2019;5(2):173–180.
Leighl NB, et al. Clin Cancer Res, 2019;25(15):4691–4700.
Maity AP, et al. JCO Oncol Pract. 2023;19:620–625.
Casagrande GMS, et al. Int J Mol Sci. 2023;24:2505.
Chen Y, et al. Neoplasma. 2019;66(4):652–660.
Aggarwal C, et al. Lung Cancer. 2021;162:42–53.
Hirahata T, et al. Cancer Inform. 2022;21:1–7.
Lindeman NI, et al. Arch Pathol Lab Med. 2018;142(3):321–346.
Detterbeck FC, et al. CHEST. 2013;143(suppl 5):7S–37S.
Merker JD, et al. J Clin Oncol. 2018;36(16):1631–1641.
US Food and Drug Administration. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). Accessed September 03, 2024. https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools
Foundation Medicine. FoundationOne^® CDx Specimen Instructions. Accessed September 03, 2024. https://www.foundationmedicine.co.uk/content/dam/rfm/uk_v2-en_uk/Downloads/M-GB-00002744_FMI_CDx_Specimen_Instructions.pdf
Foundation Medicine. FoundationOne^®Liquid CDx. Accessed September 03, 2024. https://www.foundationmedicine.com/test/foundationone-liquid-cdx#
Guardant Health. FDA Approved Guardant360^® CDx. Accessed September 03, 2024. https://www.guardantcomplete.com/products/guardant360-cdx
Guardant Health. Guardant360^® CDx Technical Information. Accessed September 03, 2024. https://www.guardantcomplete.com/assets/pdf/Guardant360-CDx-Technical-Information-US.pdf
Caris^® Life Sciences. Comprehensive Molecular Profiling. Accessed October 15, 2024. https://www.carislifesciences.com/products-and-services/molecular-profiling/
Caris^® Life Sciences. Specimen Preparation Instructions. Accessed September 03, 2024. https://www.carislifesciences.com/wp-content/uploads/2020/08/TN0252-v8_Specimen_Prep_Instructions_hi-rez.pdf
Tempus. Tempus xT Solid Tumor + Normal Match DNA Sequencing. Accessed September 03, 2024. https://www.tempus.com/oncology/genomic-profiling/xt-xr/
Tempus. Specimen Guidelines for Providers. Accessed September 03, 2024. https://www.tempus.com/wp-content/uploads/2024/11/Tempus-Onco_Specimen-Guidelines.pdf
NeoGenomics. NeoTYPE^® Lung Tumor Profile. Accessed September 03, 2024. https://neogenomics.com/test-menu/neotype-lung-tumor-profile
ThermoFisher Scientific. Oncomine^™ Dx Target Test. Accessed September 18, 2024. https://assets.thermofisher.com/TFS-Assets/LSG/brochures/oncomine-dx-target-test-brochure.pdf
Roche Diagnostics. cobas^® EGFR Mutation Test v2. Accessed September 03, 2024. https://diagnostics.roche.com/us/en/products/params/cobas-egfr-mutation-test-v2.html
Roche Diagnostics. cobas^® cfDNA Sample Preparation Kit. Accessed September 03, 2024. https://diagnostics.roche.com/us/en/products/params/cobas-cfdna-sample-preparation-kit.html
Qiagen. therascreen^® EGFR RGQ PCR kit instructions for use (handbook). Accessed September 03, 2024. https://www.qiagen.com/us/resources/resourcedetail?id=ebc6f982-739f-449f-97e6-bd0b39c08070&lang=en
Biocartis. Technical Sheet Idylla^™ EGFR Mutation Assay. Accessed September 03, 2024. https://www.biocartis.com/sites/default/files/2019-11/idylla_egfr_technical_sheet.pdf
ThermoFisher Scientific. Oncomine^™ Precision Assay. Accessed September 03, 2024. https://assets.thermofisher.com/TFS-Assets/CSD/Flyers/oncomine-precision-assay-flyer.pdf
Brown NA, et al. Am Soc Clin Oncol Educ Book. 2018;38:708–715.
College of American Pathologists. Cancer protocol templates. Lung biomarker reporting. Accessed September 03, 2024. https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

EGFR Mutations in NSCLC

Testing for EGFR Mutations in Lung Cancer Can Help Guide Treatment Decisions^2,3

NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) Recommend Testing for EGFR Mutations in NSCLC Stage IB—IIIA, IIIB (T3, N2) and Stage IV NSCLC³

Why test

Whom to test

How to test

Why test

Whom to test

How to test

EGFR Mutations Are One of the Most Common Actionable Oncogenic Drivers in NSCLC⁸

Consider Sample Type by Specimen and Assay Availability to Maximize Detection of Therapeutically Actionable Mutations

Utilize Diagnostic Assays for EGFR Mutation Testing to Help Inform Treatment Options³⁵

Browse a selection of major laboratories offering a range of biomarker testing options.

Find a list of FDA cleared or approved companion diagnostics.³⁵

Accurate Interpretation and Reporting of Biomarker Test Results May Help to Ensure an Appropriate Diagnosis⁵¹

Considerations for Your Practice

Helpful Resources

Tumor Types & Biomarkers

Explore Precision Medicine

Realizing the Potential of Precision Medicine

Latest Developments in Precision Medicine

Resources

FAQs

Find a Testing Lab

Glossary

Resource Library

My Favorites

Search

EGFR Mutations in NSCLC

Testing for EGFR Mutations in Lung Cancer Can Help Guide Treatment Decisions2,3

NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) Recommend Testing for EGFR Mutations in NSCLC Stage IB—IIIA, IIIB (T3, N2) and Stage IV NSCLC3

Why test

Whom to test

How to test

Why test

Whom to test

How to test

Footnotes

EGFR Mutations Are One of the Most Common Actionable Oncogenic Drivers in NSCLC8

Footnotes

Footnotes

Consider Sample Type by Specimen and Assay Availability to Maximize Detection of Therapeutically Actionable Mutations

Footnotes

Utilize Diagnostic Assays for EGFR Mutation Testing to Help Inform Treatment Options35

Browse a selection of major laboratories offering a range of biomarker testing options.

Find a list of FDA cleared or approved companion diagnostics.35

Accurate Interpretation and Reporting of Biomarker Test Results May Help to Ensure an Appropriate Diagnosis51

Considerations for Your Practice

Helpful Resources

Subscribe to Emails

Connect With Us

References

Share Resource

AZPrecisionMed.com

What is an AstraZeneca authorised person?

Share Resource

Testing for EGFR Mutations in Lung Cancer Can Help Guide Treatment Decisions^2,3

NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) Recommend Testing for EGFR Mutations in NSCLC Stage IB—IIIA, IIIB (T3, N2) and Stage IV NSCLC³

EGFR Mutations Are One of the Most Common Actionable Oncogenic Drivers in NSCLC⁸

Utilize Diagnostic Assays for EGFR Mutation Testing to Help Inform Treatment Options³⁵

Find a list of FDA cleared or approved companion diagnostics.³⁵

Accurate Interpretation and Reporting of Biomarker Test Results May Help to Ensure an Appropriate Diagnosis⁵¹